Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab induction study in moderately to severely active Crohn's disease
NL-OMON50722Phase 3Completed
- Sponsor
- Site Management & Monitoring
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of risankizumab in Crohn's disease, sponsored by Site Management & Monitoring. Started Sep 2018; status: completed.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON50722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50722.